Tocilizumab for hospitalized patients with COVID-19
Kevin Afra, Luke Y. C. Chen, David Sweet
Abstract
Many patients with severe coronavirus disease 2019 (COVID-19) have immune misfiring characterized by a defective interferon response followed by elevated inflammatory cytokines, notably IL-6.[1][1] Tocilizumab is a monoclonal IL-6 receptor antibody that is approved for use in inflammatory conditions
Topics & Concepts
TocilizumabCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Monoclonal antibodyMonoclonalCoronavirusImmunologyInterleukin 6Immune systemInterferonAntibodyCytokineVirologyInternal medicineDiseaseInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Inflammasome and immune disorders